Triple-negative breast cancer, defined by the lack of expression of estrogen receptorα (ERα) and progesterone receptor (PR) as well as the absence of overexpression and/or gene amplification of HER2, is a unique subtype of breast cancer with limited treatment options and poor prognosis [3, 4]. This evidence concerns the gene PGR and breast cancer.